172 related articles for article (PubMed ID: 20854925)
21. Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer.
Kluge A; Dabir S; Kern J; Nethery D; Halmos B; Ma P; Dowlati A
Int J Cancer; 2009 Oct; 125(7):1728-34. PubMed ID: 19569236
[TBL] [Abstract][Full Text] [Related]
22. Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer.
Gu L; Zhu XH; Visakorpi T; Alanen K; Mirtti T; Edmonston TB; Nevalainen MT
Anal Cell Pathol (Amst); 2010; 33(2):55-9. PubMed ID: 20966544
[TBL] [Abstract][Full Text] [Related]
23. Progesterone induction of the 11beta-hydroxysteroid dehydrogenase type 2 promoter in breast cancer cells involves coordinated recruitment of STAT5A and progesterone receptor to a distal enhancer and polymerase tracking.
Subtil-Rodríguez A; Millán-Ariño L; Quiles I; Ballaré C; Beato M; Jordan A
Mol Cell Biol; 2008 Jun; 28(11):3830-49. PubMed ID: 18378698
[TBL] [Abstract][Full Text] [Related]
24. PAX6 promotes neuroendocrine phenotypes of prostate cancer via enhancing MET/STAT5A-mediated chromatin accessibility.
Jing N; Du X; Liang Y; Tao Z; Bao S; Xiao H; Dong B; Gao WQ; Fang YX
J Exp Clin Cancer Res; 2024 May; 43(1):144. PubMed ID: 38745318
[TBL] [Abstract][Full Text] [Related]
25. Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior.
Tang JZ; Zuo ZH; Kong XJ; Steiner M; Yin Z; Perry JK; Zhu T; Liu DX; Lobie PE
Endocrinology; 2010 Jan; 151(1):43-55. PubMed ID: 19966185
[TBL] [Abstract][Full Text] [Related]
26. STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression.
Zhang Q; Wang HY; Liu X; Wasik MA
Nat Med; 2007 Nov; 13(11):1341-8. PubMed ID: 17922009
[TBL] [Abstract][Full Text] [Related]
27. HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth.
Medler TR; Craig JM; Fiorillo AA; Feeney YB; Harrell JC; Clevenger CV
Mol Cancer Res; 2016 Oct; 14(10):994-1008. PubMed ID: 27358110
[TBL] [Abstract][Full Text] [Related]
28. Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer.
Røe K; Bratland Å; Vlatkovic L; Ragnum HB; Saelen MG; Olsen DR; Marignol L; Ree AH
PLoS One; 2013; 8(5):e63723. PubMed ID: 23675504
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of STAT5a by Naa10p contributes to decreased breast cancer metastasis.
Zeng Y; Min L; Han Y; Meng L; Liu C; Xie Y; Dong B; Wang L; Jiang B; Xu H; Zhuang Q; Zhao C; Qu L; Shou C
Carcinogenesis; 2014 Oct; 35(10):2244-53. PubMed ID: 24925029
[TBL] [Abstract][Full Text] [Related]
30. STAT5 isoforms regulate colorectal cancer cell apoptosis via reduction of mitochondrial membrane potential and generation of reactive oxygen species.
Du W; Wang YC; Hong J; Su WY; Lin YW; Lu R; Xiong H; Fang JY
J Cell Physiol; 2012 Jun; 227(6):2421-9. PubMed ID: 21826656
[TBL] [Abstract][Full Text] [Related]
31. Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer.
Haddad BR; Erickson A; Udhane V; LaViolette PS; Rone JD; Kallajoki MA; See WA; Rannikko A; Mirtti T; Nevalainen MT
Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1642-1651. PubMed ID: 31292140
[TBL] [Abstract][Full Text] [Related]
32. Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer.
Erb HHH; Bodenbender J; Handle F; Diehl T; Donix L; Tsaur I; Gleave M; Haferkamp A; Huber J; Fuessel S; Juengel E; Culig Z; Thomas C
PLoS One; 2020; 15(8):e0237248. PubMed ID: 32790723
[TBL] [Abstract][Full Text] [Related]
33. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.
Casetti L; Martin-Lannerée S; Najjar I; Plo I; Augé S; Roy L; Chomel JC; Lauret E; Turhan AG; Dusanter-Fourt I
Cancer Res; 2013 Apr; 73(7):2052-8. PubMed ID: 23400594
[TBL] [Abstract][Full Text] [Related]
34. Robust gene network analysis reveals alteration of the STAT5a network as a hallmark of prostate cancer.
Reddy A; Huang CC; Liu H; Delisi C; Nevalainen MT; Szalma S; Bhanot G
Genome Inform; 2010; 24():139-53. PubMed ID: 22081596
[TBL] [Abstract][Full Text] [Related]
35. The novel quinolizidine derivate IMB-HDC inhibits STAT5a phosphorylation at 694 and 780 and promotes DNA breakage and cell apoptosis via blocking STAT5a nuclear translocation.
Zhao WL; Xing Y; Ye C; Qiu YH; Li Y; Liu XJ; Wang MY; Bi CW; Song DQ; Shao RG
Acta Pharmacol Sin; 2020 May; 41(5):686-697. PubMed ID: 31932645
[TBL] [Abstract][Full Text] [Related]
36. Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma.
He T; McColl K; Sakre N; Chen Y; Wildey G; Dowlati A
Mol Oncol; 2018 Dec; 12(12):2124-2135. PubMed ID: 30259640
[TBL] [Abstract][Full Text] [Related]
37. Differential PIAS3 expression in human malignancy.
Wang L; Banerjee S
Oncol Rep; 2004 Jun; 11(6):1319-24. PubMed ID: 15138572
[TBL] [Abstract][Full Text] [Related]
38. PIAS3, SHP2 and SOCS3 Expression patterns in Cervical Cancers: Relevance with activation and resveratrol-caused inactivation of STAT3 signaling.
Zhang P; Yang B; Yao YY; Zhong LX; Chen XY; Kong QY; Wu ML; Li C; Li H; Liu J
Gynecol Oncol; 2015 Dec; 139(3):529-35. PubMed ID: 26432044
[TBL] [Abstract][Full Text] [Related]
39. Protein inhibitor of activated STAT3 expression in lung cancer.
Kluge A; Dabir S; Vlassenbroeck I; Eisenberg R; Dowlati A
Mol Oncol; 2011 Jun; 5(3):256-64. PubMed ID: 21497567
[TBL] [Abstract][Full Text] [Related]
40. STAT5A modulates gastric cancer progression via upregulation of CD44.
Wang S; Fan R; Gao H; Ma X; Wu Y; Xing Y; Wang Y; Jia Y
Genomics; 2023 May; 115(3):110638. PubMed ID: 37196931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
